Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Capricor TherapeuticsCAPR +1.29%24 3-Year Book Growth Rate is 125.10% as of Jun. 2026. GuruFocus rates CAPR with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 1,128 Biotechnology companies, Capricor Therapeutics ranks better than 98.76% on this metric.
During the past 12 months, Capricor Therapeutics's average Book Value per Share Growth Rate was 84.50% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 125.10% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 32.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Capricor Therapeutics was 125.10% per year. The lowest was -192.40% per year. And the median was -38.85% per year.
Capricor Therapeutics (NAS:CAPR) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Capricor Therapeutics 3-Year Book Growth Rate Related Terms
CAPR vs BLSM, ZURA, OVID: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Capricor Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Capricor Therapeutics 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Capricor Therapeutics's 3-Year Book Growth Rate falls into.
Capricor Therapeutics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 125.10% mean?
Capricor Therapeutics (CAPR) has a 3-Year Book Growth Rate of 125.10% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Capricor Therapeutics and its competitors. According to the industry distribution chart, Capricor Therapeutics ranks #14 out of 1128 companies in the Biotechnology industry, placing it in the top 1.2%.
Is Capricor Therapeutics' 3-Year Book Growth Rate too high?
Capricor Therapeutics' current 3-Year Book Growth Rate is 125.10%. Based on the distribution chart, Capricor Therapeutics ranks #14 out of 1128 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Capricor Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' 3-Year Book Growth Rate compare to BLSM and ZURA?
According to the Biotechnology industry distribution chart, Capricor Therapeutics ranks #14 out of 1128 companies for 3-Year Book Growth Rate. This places Capricor Therapeutics in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Capricor Therapeutics and its competitors. Capricor Therapeutics's current 3-Year Book Growth Rate is 125.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Capricor Therapeutics (CAPR) has a current 3-Year Book Growth Rate of 125.10%. The current 3-Year Book Growth Rate is 125.10%. Capricor Therapeutics' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Capricor Therapeutics (CAPR), the current 3-Year Book Growth Rate is 125.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
24GF Score
Get the complete analysis for CAPR
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAPR has been successfully added to your 
